EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?

Reem Elajez, Dana Bakdach, Mousa Hussein, Anam Elarabi, Abdullah Mohammad, Aisha Al-Adab, Mona Al-Langawi, Merlin Thomas

Therapeutic Advances in Infectious Disease · 2026-10 · 13

DOI: 10.1177/20499361261503133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 27.10.2026. Verfasst von Reem Elajez und 7 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation- Medical research center, Qatar National Library.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aminoglycosides are widely used in dual antipseudomonal therapy for acute pulmonary exacerbations in cystic fibrosis (CF). Due to altered pharmacokinetics in CF, achieving recommended pharmacokinetic/pharmacodynamic (PK/PD) targets is challenging and the impact of target attainment on clinical outcomes remains unclear.

Objectives

To evaluate whether currently recommended aminoglycoside dosing regimens in CF achieve PK/PD targets in clinical practice, and whether target attainment correlates with clinical improvements in CF patients. Design/methods A two-year, single-center cohort study was conducted in adult CF patients receiving aminoglycoside during acute exacerbation. Aminoglycoside levels were obtained to estimate PK parameters. Clinical symptoms and pulmonary function were assessed at admission (baseline) and discharge.

Results

Fourteen treatment courses were analyzed among nine patients. Amikacin (n=10, mean dose 30.9 ± 2 mg/kg), or gentamicin (n=4, mean dose 10.5 ± 0.7 mg/kg) were administered. The target C max :MIC ratio of 8-10 was achieved in 50% of amikacin courses and none of the gentamicin courses. Most patients improved clinically, evident by symptoms’ resolution and increased ppFEV 1 . Target attainment was associated with a numerically greater ppFEV 1 improvement, though not statistically significant (P=0.29).

Conclusions

The pre-defined PK/PD target was attained in less than half of the cases treated, underscoring the need for optimized dosing strategies. Nonetheless, clinical improvement occurred regardless of target attainment. This highlights the need of larger randomized controlled studies to define the relationship between aminoglycoside PK/PD target achievement and clinical outcomes among CF patients.

Förderung

  • Hamad Medical Corporation- Medical research center
  • Qatar National Library

Zitieren

APA

Elajez, R., Bakdach, D., Hussein, M., Elarabi, A., Mohammad, A., Al-Adab, A., Al-Langawi, M., & Thomas, M. (2026). Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?. Therapeutic Advances in Infectious Disease, 13. https://doi.org/10.1177/20499361261503133

Vancouver

Elajez R, Bakdach D, Hussein M, Elarabi A, Mohammad A, Al-Adab A, et al. Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?. Therapeutic Advances in Infectious Disease. 2026;13. doi:10.1177/20499361261503133

BibTeX
@article{Elajez2026,
  author = {Elajez, Reem and Bakdach, Dana and Hussein, Mousa and Elarabi, Anam and Mohammad, Abdullah and Al-Adab, Aisha and Al-Langawi, Mona and Thomas, Merlin},
  title = {Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?},
  journal = {Therapeutic Advances in Infectious Disease},
  year = {2026},
  volume = {13},
  doi = {10.1177/20499361261503133}
}
Kostenlos starten →